Life Science Nation Newsletter  | March 15,  2018  |  Issue 257


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Mar. 8 - Mar. 14 )
Actively Seeking Early-Stage Life Science Investments, from Pre-Clinical Stage Assets to Medical Devices
Invests in Therapeutics and Clinical Testing Companies, with Focus on China Angle
Looks for Complementary Early-Stage Genomics & Big Data/AI Technologies
Invests Opportunistically in Early-Stage Life Science & Healthcare Companies
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
LSN's Sourcing & Ranking Service (SRS) provides clients with an opportunity to quickly source, vet, rank and engage with partners that are licensing global technology assets.

Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
Zishan Haroon
An interview with Zishan Haroon, Chairman and General Partner, Julz Co

- By Claire Jeong, Research Analyst, LSN
Claire Jeong

Earlier this week, I had the pleasure of speaking with Dr. Zishan "Z" Haroon, Chairman and General Partner of Julz Co. Z has been a tremendous supporter of the Redefining Early Stage Investments (RESI) Conference Series and a frequent contributor to several of our ongoing investor panels. As many of you already know, the RESI Conference is a one-day partnering conference dedicated to early-stage life sciences technologies, from therapeutics, medical devices, diagnostics, and digital health. In fact, we have recently learned that the firm's latest investment was in a company Z had met through RESI! In this interview, Z discusses his perspectives on his RESI experience, Julz's most recent investment, and some tips for fundraising CEOs.

Claire Jeong: First of all, please tell us a little bit about your background.

Z Haroon: My name is Zishan "Z" Haroon and I am the Chairman and General Partner of Julz Co, an investment management firm which invests in healthcare companies internationally including the USA, Europe, and China. I am an MD, Ph.D. by education. I graduated from Duke University and initially worked in academic and pharma research. Later, I moved into venture, private equity, and corporate/business development. I have worked on helping entrepreneurs with commercialization for many years...
By Gregory Mannix, Vice President International Business Development, LSN

Life Science Nation's Redefining Early Stage Investments (RESI) Conference series is a great opportunity to network and make connections with key players that can help move your company to the next phase. The RESI conference series, because of its unique focus and format, is by far the best opportunity for early-stage companies to meet and partner with investors and strategics. But, like everything else in life, it is competitive and it is challenging.

I have worked with many sell-side RESI attendees. Some are consistently very successful getting many good investor meetings at each and every RESI conference they attend, while others struggle to get any meetings at all.

So what is the key to success?  

Clearly, your degree of success is directly proportionate to the effort you put into it. There are 4 key elements to successful partnering:  
  1. Create a compelling and complete profile for your company and yourself on the Partnering Platform 
  2. Spend time on developing an outbound meeting request message 
  3. Request as many meetings as possible 
  4. Follow up frequently 
Yes, this is a big task and a lot of work over the weeks leading up to a conference, but the effort you put into partnering will determine the outcome. Let's have a look at each key element of your partnering strategy...

Dennis Ford
An interview with Life Science Nation's CEO Dennis Ford regarding the up and coming Redefining Early Stage Investments conference series 
- By Ying Tam, Managing Director, Health Ventures, MaRS
Ying
Tam

With the Redefining Early Stage Investments Conference headed back to MaRS on April 10th, Next Phase would like to revisit this interview between Dennis Ford (CEO, Life Science Nation) and Ying Tam (Managing Director, Health Ventures, MaRS). Read on for a discussion of how RESI's unique high-touch Partnering system and 1:1 ratio of investor to startup attendees makes RESI a standout event for fundraising CEOs.

Ying Tam, Managing Director, Health Ventures, MaRS:

Dennis, what is the key differentiator of the Redefining Early Stage Investments (RESI) Conference?

Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series:

The sweet spot - RESI is the only "dedicated" early stage global investor conference out there that I can find. We attract investor attendees from 10 categories of early-stage investors. Also, RESI is one of the very few conferences that is cross-domain, in that it features Biotech, Medtech, Diagnostics and Health IT. Many investors have multiple investment mandates covering multiple silos in the life science arena.

What is also compelling about RESI is that it is an ongoing conference series that takes place at all the major technology hubs of North America. The basic RESI format is unique in that it is held regularly every few months at these innovation hubs (an industry first) and gives both fundraising CEOs, early stage investor/partners and service providers a capability to use RESI as part of their ongoing yearly business activities. Scientist/entrepreneurs can weave themselves into the RESI conference series and dramatically increase face time with prime partnering targets. The ability to carry on that dialogue every few months greatly aids in transmitting the latest information and cultivating the relationship...

Created & Produced by